Oppenheimer Holdings Inc. assumed coverage on shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) in a report released on Tuesday. The brokerage issued an outperform rating on the stock.

SYRS has been the subject of a number of other research reports. HC Wainwright reiterated a hold rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. Zacks Investment Research cut Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, September 22nd. Cann started coverage on Syros Pharmaceuticals in a research report on Monday. They issued an outperform rating and a $28.00 price target for the company. Piper Jaffray Cos. set a $20.00 price target on Syros Pharmaceuticals and gave the stock a buy rating in a research report on Monday, November 14th. Finally, Wedbush restated an outperform rating and issued a $18.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, November 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Syros Pharmaceuticals presently has an average rating of Buy and a consensus price target of $19.60.

Syros Pharmaceuticals (NASDAQ:SYRS) opened at 13.93 on Tuesday. The company’s 50 day moving average price is $13.48 and its 200-day moving average price is $13.08. Syros Pharmaceuticals has a one year low of $8.16 and a one year high of $21.50. The stock’s market capitalization is $325.68 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Monday, November 14th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. Analysts expect that Syros Pharmaceuticals will post ($4.03) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Syros Pharmaceuticals Inc. (SYRS) Coverage Initiated by Analysts at Oppenheimer Holdings Inc.” was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/30/syros-pharmaceuticals-inc-syrs-coverage-initiated-by-analysts-at-oppenheimer-holdings-inc.html.

Institutional investors have recently made changes to their positions in the stock. Baker BROS. Advisors LP purchased a new position in shares of Syros Pharmaceuticals during the third quarter worth approximately $2,836,000. AWM Investment Company Inc. purchased a new position in shares of Syros Pharmaceuticals during the third quarter worth approximately $660,000. Morgan Stanley purchased a new position in shares of Syros Pharmaceuticals during the third quarter worth approximately $469,000. Spark Investment Management LLC purchased a new position in shares of Syros Pharmaceuticals during the third quarter worth approximately $160,000. Finally, California State Teachers Retirement System purchased a new position in shares of Syros Pharmaceuticals during the third quarter worth approximately $137,000. 54.56% of the stock is owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.